

Appendix: Tables

1.	Sales January to June 2022 and 2021	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2022 vs. YTD June 2021	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10
9.	Roche Group consolidated income statement for the six months ended 30 June 2022.....	11
10.	Roche Group core results reconciliation – Half Year 2022	12
11.	Divisional core results reconciliation – Half Year 2022.....	13
12.	Roche Group consolidated balance sheet	14
13.	Roche Group consolidated statement of cash flows	15

1. Sales January to June 2022 and 2021

CHF millions	Six months ended 30 June		% change	
	2022	2021	At CER	In CHF
Pharmaceuticals Division	22,347	21,671	3	3
United States	11,363	10,802	1	5
Europe	4,104	4,485	-4	-8
Japan	2,202	1,808	34	22
International*	4,678	4,576	2	2
Diagnostics Division	9,948	9,042	11	10
Roche Group	32,295	30,713	5	5

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2022 and 2021

CHF millions	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021
Pharmaceuticals Division	11,071	4	11,708	5	11,662	14	11,159	6	11,188	0
United States	5,510	0	5,905	0	5,798	8	5,489	2	5,874	1
Europe	2,310	15	2,125	1	2,266	19	2,072	-1	2,032	-6
Japan	956	7	1,378	60	1,320	46	1,337	69	865	3
International*	2,295	4	2,300	2	2,278	9	2,261	0	2,417	4
Diagnostics Division	4,712	48	4,263	18	4,455	8	5,286	24	4,662	0
Roche Group	15,783	14	15,971	8	16,117	12	16,445	11	15,850	0

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2022 vs. YTD June 2021

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	2,910	17	2,140	11	539	34	-	-	231	43
Perjeta	2,061	5	740	1	457	-17	120	-1	744	34
Hemlibra	1,826	30	1,098	26	360	30	180	19	188	89
Tecentriq	1,758	11	951	13	383	19	218	-7	206	9
Actemra/RoActemra	1,455	-10	664	-7	420	-3	174	4	197	-37
Herceptin	1,179	-16	263	-27	233	-11	28	-28	655	-11
Avastin	1,142	-29	342	-38	116	-53	263	-13	421	-20
MabThera/Rituxan	1,117	-21	691	-22	105	-17	17	-8	304	-19
Kadcyla	1,074	14	415	-1	350	10	68	23	241	52
Xolair	1,025	11	1,025	11	-	-	-	-	-	-
Alecensa	745	19	207	19	149	7	114	6	275	37
Ronapreve	609	11	-	-	65	-86	467	-	77	-30
Lucentis	572	-17	572	-17	-	-	-	-	-	-
Activase/TNKase	559	-10	531	-10	-	-	-	-	28	1
Evrystdi	500	106	227	32	152	489	38	-	83	65
Esbriet	457	-14	313	-17	127	-2	-	-	17	-36
Gazyva	349	8	161	2	95	-6	28	-2	65	88
Phesgo	325	241	138	155	163	338	-	-	24	403
Pulmozyme	279	0	184	2	51	-11	-	-	44	4
CellCept	270	-8	20	-16	68	-7	29	-8	153	-6
Polivy	177	91	77	86	46	16	43	**	11	97
Erivedge	131	2	82	-3	30	6	-	-	19	22

Enspryng	84	132	24	192	4	**	55	102	1	201
Vabysmo	109	-	101	-	-	-	7	-	1	-
Rozlytrek	34	54	22	44	5	79	3	18	4	262
Cotellic	24	4	7	8	8	-9	-	-	9	16
Gavreto	12	-	9	-	3	-	-	-	-	-
Xofluza	4	-	1	-	-	-	-	-	3	**
Susvimo	2	-	2	-	-	-	-	-	-	-
Pharma other	1,558	-13	356	-19	175	-21	350	-2	677	-14
Pharma total sales	22,347	3	11,363	1	4,104	-4	2,202	34	4,678	2

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021
Ocrevus	1,212	31	1,283	7	1,334	25	1,449	18	1,461	17
Perjeta	980	7	1,006	2	981	3	993	1	1,068	9
Hemlibra	732	58	779	37	850	38	853	30	973	31
Tecentriq	824	31	878	23	838	17	825	8	933	13
Actemra/RoActemra	863	12	1,048	57	872	21	792	3	663	-23
Herceptin	641	-35	665	-26	633	-6	607	-19	572	-11
Avastin	782	-40	745	-37	666	-30	581	-32	561	-27
MabThera/Rituxan	674	-34	589	-42	597	-26	564	-21	553	-20
Kadcyla	481	21	501	11	522	16	511	9	563	18
Xolair	478	3	529	8	526	14	456	9	569	13
Alecensa	333	25	357	18	368	15	361	23	384	16
Ronapreve	429	-	489	-	546	-	587	272	22	-91
Lucentis	328	2	352	-10	336	2	256	-26	316	-9
Activase/TNKase	294	3	323	3	391	22	247	-20	312	1
Evrysdi	163	-	153	*	206	347	226	189	274	65
Esbriet	270	1	263	-5	250	-7	241	-6	216	-21
Gazyva	169	18	177	10	177	10	165	7	184	9
Phesgo	67	-	117	*	127	*	146	410	179	168
Pulmozyme	137	-13	138	-7	152	5	136	-3	143	2
CellCept	144	-3	155	3	139	-2	134	-12	136	-3

* Over 500%

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021
Ocrevus	935	28	930	0	998	23	1,050	12	1,090	10
Perjeta	343	-3	376	2	337	-2	362	-1	378	4
Hemlibra	439	49	480	36	498	33	520	28	578	24
Tecentriq	416	19	461	10	416	2	446	10	505	15
Actemra/RoActemra	384	3	611	143	461	67	380	22	284	-31
Herceptin	157	-55	153	-52	135	-34	144	-26	119	-29
Avastin	243	-46	215	-50	177	-45	178	-39	164	-36
MabThera/Rituxan	429	-37	342	-49	355	-32	347	-20	344	-24
Kadcyla	201	6	212	0	200	3	204	0	211	-1
Xolair	478	3	529	8	526	14	456	9	569	13
Alecensa	90	13	96	9	103	18	99	25	108	14
Ronapreve	-	-	-	-	-	-	-	-	-	-
Lucentis	328	2	352	-10	336	2	256	-26	316	-9
Activase/TNKase	279	2	309	2	376	22	234	-21	297	1
Evrysdi	87	-	102	*	97	112	109	36	118	28
Esbriet	188	0	195	-2	176	-7	170	-4	143	-28
Gazyva	79	28	79	3	81	11	75	0	86	3
Phesgo	32	-	46	*	53	236	60	187	78	134
Pulmozyme	88	-21	89	-10	101	6	87	0	97	5
CellCept	12	-18	12	-18	10	-31	10	-15	10	-17

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021
Ocrevus	205	40	267	36	227	26	280	34	259	34
Perjeta	277	2	269	-8	265	-8	228	-21	229	-12
Hemlibra	156	123	148	26	169	53	170	31	190	29
Tecentriq	171	20	181	16	193	41	183	14	200	24
Actemra/RoActemra	217	20	207	10	252	18	220	-4	200	-2
Herceptin	131	-25	130	-20	137	-3	122	-13	111	-9
Avastin	119	-69	89	-69	84	-49	58	-56	58	-49
MabThera/Rituxan	65	-21	69	-33	65	-13	54	-19	51	-16
Kadcyla	169	29	172	16	179	16	172	8	178	12
Xolair	-	-	-	-	-	-	-	-	-	-
Alecensa	74	19	73	7	76	9	75	5	74	8
Ronapreve	317	-	85	-	159	-	62	-61	3	-99
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Evrysdi	27	-	35	-	51	*	68	*	84	227
Esbriet	68	9	65	0	67	0	62	-5	65	1
Gazyva	55	19	61	10	56	2	46	-5	49	-8
Phesgo	32	-	53	-	71	-	76	*	87	188
Pulmozyme	30	-7	29	-10	28	-15	26	-11	25	-12
CellCept	39	17	38	-2	39	3	34	-7	34	-7

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	68	-2	68	0	68	-3	59	-1	61	-1
Hemlibra	87	21	94	29	105	30	84	15	96	24
Tecentriq	137	86	130	75	131	34	107	-5	111	-9
Actemra/RoActemra	98	15	103	25	97	5	87	12	87	-2
Herceptin	21	-37	20	-37	19	-36	15	-30	13	-27
Avastin	169	0	172	5	172	0	131	-12	132	-13
MabThera/Rituxan	10	-34	11	-30	11	-17	8	-15	9	-2
Kadcyla	33	57	34	59	36	42	32	28	36	20
Xolair	-	-	-	-	-	-	-	-	-	-
Alecensa	63	10	63	11	66	5	54	7	60	5
Ronapreve	-	-	360	-	285	-	483	-	-16	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Evrysdi	-	-	3	-	16	-	17	-	21	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Gazyva	17	-17	16	10	15	-7	15	8	13	-10
Phesgo	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	-	-	-	1	22	-	-	-	-
CellCept	18	-7	17	-7	18	-9	14	-8	15	-9

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020	Q4 2021	% change vs. Q4 2020	Q1 2022	% change vs. Q1 2021	Q2 2022	% change vs. Q2 2021
Ocrevus	72	41	86	35	109	51	119	29	112	62
Perjeta	292	34	293	16	311	24	344	32	400	37
Hemlibra	50	92	57	138	78	55	79	63	109	115
Tecentriq	100	56	106	62	98	24	89	0	117	17
Actemra/RoActemra	164	27	127	-14	62	-55	105	-30	92	-44
Herceptin	332	-22	362	-7	342	17	326	-18	329	-3
Avastin	251	-20	269	-11	233	-24	214	-23	207	-17
MabThera/Rituxan	170	-30	167	-25	166	-15	155	-23	149	-13
Kadcyla	78	35	83	16	107	38	103	26	138	81
Xolair	-	-	-	-	-	-	-	-	-	-
Alecensa	106	59	125	40	123	25	133	45	142	29
Ronapreve	112	-	44	-	102	-	42	-	35	-68
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	15	6	14	17	15	7	13	-3	15	4
Evrysdi	49	-	13	-	42	**	32	**	51	-5
Esbriet	14	-7	3	-73	7	-36	9	-36	8	-36
Gazyva	18	23	21	43	25	56	29	75	36	101
Phesgo	3	-	18	-	3	**	10	**	14	278
Pulmozyme	19	40	20	12	22	45	23	-4	21	14
CellCept	75	-8	88	13	72	3	76	-14	77	3

* Asia-Pacific, CEETRIS (Central Eastern Europe, Turkey, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

9. Roche Group consolidated income statement for the six months ended 30 June 2022

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	22,347	9,948	-	32,295
Royalties and other operating income	1,918	25	-	1,943
Cost of sales	(5,029)	(4,958)	-	(9,987)
Marketing and distribution	(3,112)	(1,373)	-	(4,485)
Research and development	(5,994)	(905)	-	(6,899)
General and administration	(770)	(271)	(279)	(1,320)
Operating profit	9,360	2,466	(279)	11,547
Financing costs				(304)
Other financial income (expense)				(258)
Profit before taxes				10,985
Income taxes				(1,824)
Net income				9,161
Attributable to				
- Roche shareholders				8,530
- Non-controlling interests				631
Earnings per share and non-voting equity security				
Basic (CHF)				10.65
Diluted (CHF)				10.54

10. Roche Group core results reconciliation – Half Year 2022

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	32,295	-	-	-	-	-	-	-	-	32,295
Royalties and other operating income	1,943	-	-	-	-	-	-	-	-	1,943
Cost of sales	(9,987)	60	286	336	-	-	-	-	-	(9,305)
Marketing and distribution	(4,485)	9	17	-	-	-	-	-	-	(4,459)
Research and development	(6,899)	19	165	87	-	-	-	-	-	(6,628)
General and administration	(1,320)	178	-	-	(17)	(19)	-	-	-	(1,178)
Operating profit	11,547	266	468	423	(17)	(19)	-	-	-	12,668
Financing costs	(304)	-	-	-	2	2	-	-	-	(300)
Other financial income (expense)	(258)	-	-	-	-	-	-	-	-	(258)
Profit before taxes	10,985	266	468	423	(15)	(17)	-	-	-	12,110
Income taxes	(1,824)	(48)	(42)	(74)	-	6	-	-	32	(1,950)
Net income	9,161	218	426	349	(15)	(11)	-	-	32	10,160
Attributable to										
- Roche shareholders	8,530	208	425	349	(15)	(11)	-	-	32	9,518
- Non-controlling interests	631	10	1	-	-	-	-	-	-	642
EPS - diluted (CHF)	10.54	0.26	0.52	0.43	(0.02)	(0.01)	-	-	0.04	11.76

11. Divisional core results reconciliation – Half Year 2022

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	22,347	-	-	-	-	-	-	22,347
Royalties and other operating income	1,918	-	-	-	-	-	-	1,918
Cost of sales	(5,029)	49	214	336	-	-	-	(4,430)
Marketing and distribution	(3,112)	9	7	-	-	-	-	(3,096)
Research and development	(5,994)	17	161	87	-	-	-	(5,729)
General and administration	(770)	88	-	-	4	(14)	-	(692)
Operating profit	9,360	163	382	423	4	(14)	-	10,318
Diagnostics								
Sales	9,948	-	-	-	-	-	-	9,948
Royalties and other operating income	25	-	-	-	-	-	-	25
Cost of sales	(4,958)	11	72	-	-	-	-	(4,875)
Marketing and distribution	(1,373)	-	10	-	-	-	-	(1,363)
Research and development	(905)	2	4	-	-	-	-	(899)
General and administration	(271)	15	-	-	(21)	1	-	(276)
Operating profit	2,466	28	86	-	(21)	1	-	2,560
Corporate								
General and administration	(279)	75	-	-	-	(6)	-	(210)
Operating profit	(279)	75	-	-	-	(6)	-	(210)

12. Roche Group consolidated balance sheet

in millions of CHF	30 June 2022	31 December 2021	31 December 2020
Non-current assets			
Property, plant and equipment	23,107	23,163	22,158
Right-of-use assets	1,217	1,249	1,112
Goodwill	11,160	10,809	9,249
Intangible assets	11,735	12,117	12,017
Deferred tax assets	5,827	5,583	5,459
Defined benefit plan assets	1,323	1,498	967
Other non-current assets	2,046	2,271	2,234
Total non-current assets	56,415	56,690	53,196
Current assets			
Inventories	8,292	7,715	7,194
Accounts receivable	10,809	10,806	10,154
Current income tax assets	269	320	149
Other current assets	4,143	3,755	3,111
Marketable securities	2,493	6,181	6,607
Cash and cash equivalents	4,315	6,850	5,727
Total current assets	30,321	35,627	32,942
Total assets	86,736	92,317	86,138
Non-current liabilities			
Long-term debt	(22,369)	(16,076)	(10,220)
Net deferred tax liabilities	(690)	(628)	(353)
Defined benefit plan liabilities	(4,548)	(6,103)	(7,831)
Provisions	(1,427)	(1,442)	(1,453)
Other non-current liabilities	(1,347)	(1,307)	(1,107)
Total non-current liabilities	(30,381)	(25,556)	(20,964)
Current liabilities			
Short-term debt	(5,381)	(15,122)	(3,996)
Current income tax liabilities	(3,005)	(3,002)	(3,679)
Provisions	(2,249)	(2,526)	(1,836)
Accounts payable	(3,896)	(4,637)	(4,121)
Other current liabilities	(12,878)	(13,129)	(11,769)
Total current liabilities	(27,409)	(38,416)	(25,401)
Total liabilities	(57,790)	(63,972)	(46,365)
Total net assets	28,946	28,345	39,773
Equity			
Capital and reserves attributable to Roche shareholders	25,189	24,489	36,341
Equity attributable to non-controlling interests	3,757	3,856	3,432
Total equity	28,946	28,345	39,773

13. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2022	HY 2021
Cash flows from operating activities		
Cash generated from operations	14,522	13,324
(Increase) decrease in net working capital	(2,052)	(2,616)
Payments made for defined benefit plans	(290)	(288)
Utilisation of provisions	(527)	(511)
Disposal of products	338	484
Other operating cash flows	-	2
Cash flows from operating activities, before income taxes paid	11,991	10,395
Income taxes paid	(2,482)	(2,183)
Total cash flows from operating activities	9,509	8,212
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,685)	(1,759)
Purchase of intangible assets	(341)	(335)
Disposal of property, plant and equipment	38	38
Disposal of intangible assets	-	-
Business combinations	(41)	(1,822)
Divestment of subsidiaries	-	-
Interest and dividends received	2	1
Sales of marketable securities	101	129
Purchases of marketable securities	(132)	(99)
Sales (purchases) of money market instruments and time accounts over three months, net	3,547	3,633
Other investing cash flows	(16)	258
Total cash flows from investing activities	1,473	44
Cash flows from financing activities		
Proceeds from issue of bonds and notes	7,642	1,391
Redemption and repurchase of bonds and notes	-	(1,266)
Increase (decrease) in commercial paper	1,802	191
Increase (decrease) in other debt	(13,527)	(19)
Hedging and collateral arrangements	(534)	(324)
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(228)	(243)
Principal portion of lease liabilities paid	(186)	(187)
Dividends paid	(7,672)	(7,955)
Equity-settled equity compensation plans, net of transactions in own equity	(611)	(644)
Other financing cash flows	(1)	-
Total cash flows from financing activities	(13,315)	(9,056)
Net effect of currency translation on cash and cash equivalents	(202)	73
Increase (decrease) in cash and cash equivalents	(2,535)	(727)
Cash and cash equivalents at beginning of period	6,850	5,727
Cash and cash equivalents at end of period	4,315	5,000